<DOC>
	<DOCNO>NCT01447485</DOCNO>
	<brief_summary>This study ass pharmacokinetics safety follow single dose valsartan Japanese pediatric patient hypertension , chronic kidney disease , nephrotic syndrome .</brief_summary>
	<brief_title>Pharmacokinetics Following Single-dose Valsartan Japanese Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Japanese pediatric patient hypertension , chronic kidney disease , nephrotic syndrome GFR &lt; 30 mL/min/1.73 m2 Inability safely tolerate temporary discontinuation concomitant antihypertensive medication ( expect amlodipine atenolol ) 24 hour prior study drug administration study completion . Inability safely tolerate temporary discontinuation drug know suspected effect hepatic renal clearance capacity 24 hour prior study drug administration study completion ( include drug know cause induction inhibition hepatic enzyme ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hypertension , chronic kidney disease</keyword>
	<keyword>nephrotic syndrome</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>